Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro

Journal of Controlled Release

Volumn 144, Issue 2, 2010, Pages 118-126

  Cruz, Luis J ^a   Tacken, Paul J ^a   Fokkink, Remco ^b   Joosten, Ben ^a   Stuart, Martien Cohen ^b   Albericio, Fernando ^c   Torensma, Ruurd ^a   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Biodegradation; Delivery vehicle; Immunogenicity; Microparticle; Nanoparticle; PLGA; Targeting

Indexed keywords

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELLS; BLOOD CELLS; C-TYPE LECTINS; DELIVERY VEHICLE; DENDRITIC CELLS; FC-RECEPTORS; HUMAN DENDRITIC CELLS; IMMUNE MODULATORS; IMMUNOGENICITY; IN-VITRO; LIPID LAYERS; MICRO PARTICLES; MICROPARTICLE; NON-TARGETED; SIGN-ON; SLOW RELEASE; T-CELL RESPONSE; TARGETED DELIVERY; VACCINE DELIVERY;

ANTIBODIES; BIODEGRADATION; BLOOD; DEGRADATION; DENDRIMERS; MICROBIOLOGY; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; VACCINES;

ANTIGENS;

CD209 ANTIGEN; COMPLEMENT RECEPTOR; DRUG CARRIER; FC RECEPTOR; LECTIN; MICROPARTICLE; NANOCARRIER; POLYGLACTIN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; HUMAN; HUMAN CELL; MICROENCAPSULATION; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DEGRADATION; T LYMPHOCYTE; VACCINE PRODUCTION;

ANTIBODIES; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS; CELL ADHESION MOLECULES; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HUMANS; LACTIC ACID; LECTINS, C-TYPE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; RECEPTORS, CELL SURFACE; VACCINES;

EID: 77952674646     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.02.013     Document Type: Article

References (36)

1. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
2. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007, 7:790-802.
3. Fahmy T.M., Demento S.L., Caplan M.J., Mellman I., Saltzman W.M. Design opportunities for actively targeted nanoparticle vaccines. Nanomed. 2008, 3:343-355.
4. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440:808-812.
5. Elamanchili P., Lutsiak C.M., Hamdy S., Diwan M., Samuel J. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J. Immunother. 2007, 30:378-395.
6. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., Groettrup M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26:1626-1637.
7. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 2008, 38:1404-1413.
8. Kwon Y.J., James E., Shastri N., Frechet J.M.J. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. PNAS 2005, 102:18264-18268.
9. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., Lee L.K., Swartz M.A., Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25:1159-1164.
10. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d, l-lactide-co-glycolide) and its derivatives. J. Control. Release 2008, 125:193-209.
11. Chong C.S.W., Cao M., Wong W.W., Fischer K.P., Addison W.R., Kwon G.S., Tyrrell D.L., Samuel J. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J. Control. Release 2005, 102:85-99.
12. Raghuvanshi R.S., Katare Y.K., Lalwani K., Ali M.M., Singh O., Panda A.K. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int. J. Pharm. 2002, 245:109-121.
13. Solbrig C.M., Saucier-Sawyer J.K., Cody V., Saltzman W.M., Hanlon D.J. Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol. Pharm. 2007, 4:47-57.
14. Bazile D., Prudhomme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard M. Stealth Me.Peg-Pla nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 1995, 84:493-498.
15. Muller R.H., Wallis K.H. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int. J. Pharm. 1993, 89:25-31.
16. Pereira C.F., Torensma R., Hebeda K.M., Kretz-Rommel A., Faas S.J., Figdor C.G., Adema G.J. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model. J. Immunother. 2007, 30:705-714.
17. Kretz-Rommel A., Qin F., Dakappagari N., Torensma R., Faas S., Wu D., Bowdish K.S. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J. Immunother. 2007, 30:715-726.
18. Tacken P.J., de Vries I.J., Gijzen K., Joosten B., Wu D., Rother R.P., Faas S.J., Punt C.J., Torensma R., Adema G.J., Figdor C.G. Effective induction of naive and recall T cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005, 106:1278-1285.
19. Thomas T.C., Rollins S.A., Rother R.P., Giannoni M.A., Hartman S.L., Elliott E.A., Nye S.H., Matis L.A., Squinto S.P., Evans M.J. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 1996, 33:1389-1401.
20. Hillmen P., Young N.S., Schubert J., Brodsky R.A., Socie G., Muus P., Roth A., Szer J., Elebute M.O., Nakamura R., Browne P., Risitano A.M., Hill A., Schrezenmeier H., Fu C.L., Maciejewski J., Rollins S.A., Mojcik C.F., Rother R.P., Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 2006, 355:1233-1243.
21. Quaranta V., Walker L.E., Pellegrino M.A., Ferrone S. Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent. J. Immunol. 1980, 125:1421-1425.
22. Chianese-Bullock K.A., Irvin W.P., Petroni G.R., Murphy C., Smolkin M., Olson W.C., Coleman E., Boerner S.A., Nail C.J., Neese P.Y., Yuan A., Hogan K.T., Slingluff C.L. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J. Immunother. 2008, 31:420-430.
23. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., Yuan L., Chisari F.V., Furze J., Bartholomeuz R., Chesnut R.W. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 1995, 95:341-349.
24. Cruz L.J., Iglesias E., Aguilar J.C., Gonzalez L.J., Reyes O., Albericio F., Andreu D. A comparative study of different presentation strategies for an HIV peptide immunogen. Bioconjug. Chem. 2004, 15:112-120.
25. Bykovskaia S.N., Shurin G.V., Graner S., Bunker M.L., Olson W., Thomas R., Shurin M.R., Marks S., Storkus W.J., Shogan J. Differentiation of immunostimulatory stem-cell- and monocyte-derived dendritic cells involves maturation of intracellular compartments responsible for antigen presentation and secretion. Stem Cells 2002, 20:380-393.
26. Reis R.C., Sorgine M.H., Coelho-Sampaio T. A novel methodology for the investigation of intracellular proteolytic processing in intact cells. Eur. J. Cell. Biol. 1998, 75:192-197.
27. Voss E.W., Workman C.J., Mummert M.E. Detection of protease activity using a fluorescence-enhancement globular substrate. Biotechniques 1996, 20:286-291.
28. Duncanson W.J., Figa M.A., Hallock K., Zalipsky S., Hamilton J.A., Wong J.Y. Targeted binding of PLA microparticles with lipid-PEG-tethered ligands. Biomaterials 2007, 28:4991-4999.
29. Li Y.P., Pei Y.Y., Zhang X.Y., Gu Z.H., Zhou Z.H., Yuan W.F., Zhou J.J., Zhu J.H., Gao X.J. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Release 2001, 71:203-211.
30. Siepmann J., Elkharraz K., Siepmann F., Klose D. How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment. Biomacromolecules 2005, 6:2312-2319.
31. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., Cheong C., Liu K., Lee H.W., Park C.G., Steinman R.M., Nussenzweig M.C. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111.
32. van Broekhoven C.L., Parish C.R., Demangel C., Britton W.J., Altin J.G. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 2004, 64:4357-4365.
33. Badiee A., Davies N., McDonald K., Radford K., Michiue H., Hart D., Kato M. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007, 25:4757-4766.
34. Mohamed F., van der Walle C.F. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J. Pharm. Sci. 2008, 97:71-87.
35. Duhamel R.C., Whitehead J.S. Prevention of nonspecific binding of avidin. Methods Enzymol. 1990, 184:201-207.
36. Kato M., McDonald K.J., Khan S., Ross I.L., Vuckovic S., Chen K., Munster D., MacDonald K.P.A., Hart D.N.J. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int. Immunol. 2006, 18:857-869.